Clinical Trial Update: Early-Phase Study to Assess Inhibitor Ribociclib in Patients With Recurrent Glioblastoma or Anaplastic Glioma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma or anaplastic glioma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Glioma

Drugs mentioned

• KISQALI (ribociclib)

Snippet

Sponsor: University of Virginia | Conditions: Glioblastoma, Glioma | Phase 1 | Status: UNKNOWN